Characterization of brivanib pharmacokinetics and exposure-response (E-R): Relationship of fatigue in patients with advanced and metastatic solid tumors

被引：0
|
作者：
Wang, X.
Syed, S.
Masson, E.
Walters, I. B.
Roy, A.
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Bristol Myers Squibb, Wallingford, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3095
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Exposure-Response (E-R) Analysis to Support Benefit-Risk Assessment of Ipilimumab 3 vs 10 mg/kg in Patients with Advanced Melanoma
    Vezina, Heather E.
    Wang, Shelly
    Statkevich, Paul
    Bello, Akintunde
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S34 - S34
  • [32] Exposure-response (E-R) analysis of efficacy for avelumab in combination with axitinib in patients with advanced renal cell carcinoma (aRCC) in JAVELIN Renal 101.
    Bello, Carlo
    Brar, Satjit
    Masters, Joanna C.
    Khandelwal, Akash
    Novakovic, Ana M.
    Ruiz-Garcia, Ana
    Hibma, Jennifer
    CANCER RESEARCH, 2021, 81 (13)
  • [33] Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer.
    Zhu, Min
    Tang, Rui
    Doshi, Sameer
    Oliner, Kelly S.
    Kathman, Steven
    Gisleskog, Per Olsson
    Dubey, Sarita
    Jiang, Yizhou
    Donehower, Ross C.
    Iveson, Timothy
    Loh, Elwyn
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma
    Ou, Ying
    Doshi, Sameer
    Anh Nguyen
    Jonsson, Fredrik
    Aggarwal, Sanjay
    Rajangam, Kanya
    Dimopoulos, Meletios A.
    Stewart, A. Keith
    Badros, Ashraf
    Papadopoulos, Kyriakos P.
    Siegel, David
    Jagannath, Sundar
    Vij, Ravi
    Niesvizky, Ruben
    Graham, Richard
    Visich, Jenn
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (05): : 663 - 677
  • [35] Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients
    Struemper, Herbert
    Thapar, Mita
    Gordon, David
    Roth, David
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [36] A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
    Jonker, D. J.
    Rosen, L. S.
    Sawyer, M. B.
    de Braud, F.
    Wilding, G.
    Sweeney, C. J.
    Jayson, G. C.
    McArthur, G. A.
    Rustin, G.
    Goss, G.
    Kantor, J.
    Velasquez, L.
    Syed, S.
    Mokliatchouk, O.
    Feltquate, D. M.
    Kollia, G.
    Nuyten, D. S. A.
    Galbraith, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1413 - 1419
  • [37] Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis
    Luo, Melody
    Parasrampuria, Dolly A.
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    Nahi, Hareth
    Heuck, Christoph
    Qi, Ming
    Sun, Steven
    Clemens, Pamela L.
    Zhou, Honghui
    Sun, Yu-Nien
    Xu, Steven
    BLOOD, 2019, 134
  • [38] Exposure-response (E-R) assessments as tools for dose selection of anti-HIV drugs.
    Sekar, VJ
    Kong, LH
    Wang, D
    Rajagopalan, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P90 - P90
  • [39] EXPOSURE-RESPONSE (E-R) ANALYSIS FOR SELECTION OF OPTIMAL DOSAGE REGIMEN OF ANIFROLUMAB IN PATIENTS (PTS) WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Santiago, L. C.
    Wang, B.
    Brohawn, P.
    Wang, L.
    Illei, G.
    Roskos, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 865 - 866
  • [40] Tislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors
    Wu, C-Y.
    Budha, N.
    Gao, Y.
    Castro, H.
    Nkobena, A.
    Ben, Y.
    Sahasranaman, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 182 - +
12345